```html

Zollinger‑Ellison Syndrome (Gastrinoma): A Comprehensive Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by one or more gastrin‑producing tumors (gastrinomas) that most commonly arise in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, which in turn stimulates the stomach lining to produce large volumes of gastric acid. The resulting hyperacidity leads to severe peptic ulcer disease, diarrhea, and malabsorption.

Who it affects: ZES can occur at any age but most often presents in adults between 30 and 60 years. Men and women are affected equally. Approximately 20‑30 % of cases are associated with multiple endocrine neoplasia type 1 (MEN‑1), an inherited syndrome that also predisposes individuals to tumors of the parathyroid and pituitary glands.

Prevalence: The estimated incidence is 0.5–2 cases per million people per year, making it one of the rarest functional neuroendocrine tumors. Because many patients develop ulcers that are initially attributed to Helicobacter pylori infection or non‑steroidal anti‑inflammatory drug (NSAID) use, the true prevalence may be mildly underestimated.

Sources: Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); WHO Classification of Tumours of the Digestive System, 5th Ed.

Symptoms

Symptoms arise from two main mechanisms: (1) excess gastric acid causing ulcer disease, and (2) the tumor itself (mass effect or metastasis). Not everyone experiences every symptom.

Acid‑Related Symptoms

• Recurrent peptic ulcers – often multiple, large, and located beyond the duodenum (e.g., jejunum).
• Severe heartburn or acid reflux – burning sensation that may not improve with over‑the‑counter antacids.
• Abdominal pain – crampy, especially after meals.
• Chronic diarrhea – watery, sometimes fatty (steatorrhea) due to acid inactivation of pancreatic enzymes.
• Nausea and vomiting – can be triggered by the high acid load.
• Weight loss – secondary to malabsorption and reduced intake because of pain.

Mass‑Related Symptoms (if tumor is large or metastasized)

• Abdominal mass or fullness – palpable in the upper abdomen.
• Back or flank pain – may indicate pancreatic involvement.
• Jaundice – if a tumor compresses the bile duct.
• Fatigue, anemia – from chronic blood loss in ulcers.

Symptoms Associated with MEN‑1

• Hyperparathyroidism (high calcium, kidney stones)
• Pituitary adenomas (headaches, vision changes)

Causes and Risk Factors

Primary Cause

ZES is caused by a gastrinoma—a neuroendocrine tumor that secretes gastrin. About 70‑80 % are sporadic (no inherited mutation), while 20‑30 % are linked to MEN‑1, an autosomal‑dominant mutation in the MEN1 tumor suppressor gene.

Risk Factors

• Family history of MEN‑1 or other endocrine tumor syndromes.
• Genetic mutations in MEN1 or, rarely, CDKN1B.
• Previous neuroendocrine tumors – individuals with a history of pancreatic or duodenal neuroendocrine neoplasms have a higher chance of developing a gastrinoma.
• Age and sex – no strong sex predilection; incidence rises after the third decade.

Diagnosis

Diagnosing ZES requires confirming both hypergastrinemia and gastric acid hypersecretion, then locating the tumor.

Step 1: Biochemical Confirmation

• Fasting serum gastrin level – a level > 1000 pg/mL (or > 10× the upper limit) is highly suggestive, especially when accompanied by low gastric pH (< 2).
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin (≥ 120 pg/mL increase) is diagnostic when baseline gastrin is elevated but not diagnostic alone.
• Gastric pH measurement – confirms acid hypersecretion; usually performed during endoscopy.

Step 2: Imaging to Locate the Tumor

• Endoscopic ultrasound (EUS) – high sensitivity (up to 85 %) for small duodenal or pancreatic lesions.
• Multiphasic contrast‑enhanced CT or MRI – identifies larger lesions and metastatic spread.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – functional imaging useful when conventional studies are negative.
• Selective arterial secretagogue injection (SASI) test – invasive, used rarely for equivocal cases.

Step 3: Staging

Once located, tumors are staged using the TNM system for pancreatic neuroendocrine tumors (e.g., AJCC 8th edition). Staging determines resectability and guides management.

Treatment Options

Management combines acid control, tumor removal when feasible, and long‑term surveillance.

1. Acid–Suppressive Therapy (First‑Line)

• High‑dose proton pump inhibitors (PPIs) – omeprazole 60 mg daily, esomeprazole 80 mg daily, or equivalent. PPIs are the cornerstone and often required lifelong.
• H2‑receptor antagonists (e.g., ranitidine) are less effective and rarely used alone.

Goal: keep gastric pH ≥ 4 to heal ulcers and prevent recurrence.

2. Surgical Management

• Curative resection – enucleation or pancreaticoduodenectomy (Whipple) for localized tumors.
• Debulking surgery – reduces tumor burden when metastases are present; may improve symptom control.
• Lymph node dissection – recommended because gastrinomas frequently metastasize to regional nodes.

Patients without MEN‑1 have higher cure rates (≈ 60‑70 %) after complete resection; those with MEN‑1 often require repeated surgeries.

3. Medical Therapy for Unresectable or Metastatic Disease

• Somatostatin analogues (octreotide LAR, lanreotide) – inhibit gastrin release and may stabilize tumor growth.
• Targeted therapy – everolimus or sunitinib, approved for progressive pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for tumors expressing somatostatin receptors.
• Chemotherapy – rarely needed; reserved for high‑grade (G3) neuroendocrine carcinomas.

4. Lifestyle and Supportive Measures

• Avoid NSAIDs, aspirin, and ulcerogenic medications.
• Limit alcohol and caffeine, which can aggravate acid secretion.
• Eat small, frequent meals; avoid large fatty meals that delay gastric emptying.
• Maintain adequate calcium and vitamin D intake, especially if PPIs are used long‑term.

Living with Zollinger‑Ellison Syndrome (Gastrinoma)

Medication Adherence

Take PPIs exactly as prescribed; missing doses can cause rebound hyperacidity and ulcer bleed. Set a daily alarm or use a pill‑box.

Regular Monitoring

• Serum gastrin level and fasting gastric pH every 6–12 months.
• Endoscopic surveillance every 1–2 years to assess ulcer healing.
• Imaging (CT/MRI or PET) annually if tumor remains in situ or metastasized.

Nutrition

Because chronic diarrhea can cause nutrient deficiencies, consider:

• Supplemental pancreatic enzymes if steatorrhea persists.
• Vitamin B12, iron, calcium, and vitamin D labs annually.
• Consult a dietitian familiar with high‑acid conditions.

Psychosocial Support

Living with a rare chronic disease can be stressful. Joining support groups (e.g., Neuroendocrine Tumor Patient Foundation) and seeking counseling can improve quality of life.

Work and Daily Activities

Most patients can maintain normal employment once acid control is achieved. However, inform employers about the need for occasional medical appointments and the possibility of fatigue from chronic disease or medication side‑effects.

Prevention

Because most gastrinomas arise spontaneously, primary prevention is limited. However, the following steps can reduce risk or identify disease early:

• Genetic counseling for individuals with a family history of MEN‑1; consider testing for MEN1 mutations.
• Avoid chronic gastric irritation – limit long‑term NSAID use and treat H. pylori infection promptly.
• Regular health check‑ups for patients with known MEN‑1, including serum calcium, fasting gastrin, and imaging every 1–2 years.

Complications

If untreated or poorly controlled, ZES can lead to serious health problems:

• Perforated peptic ulcer – requires emergency surgery.
• Upper gastrointestinal bleeding – can be life‑threatening.
• Severe malabsorption – resulting in weight loss, anemia, osteoporosis.
• Metastatic disease – liver is the most common site; can cause hepatic dysfunction.
• Gastric carcinoid tumors – chronic acid hypersecretion predisposes to entero‑chromaffin‑like cell hyperplasia.
• Renal stones – from hypercalcemia in MEN‑1 patients.

When to Seek Emergency Care

---

**References** (accessed 2024):

• Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Gastrinoma (Zollinger‑Ellison Syndrome). https://www.niddk.nih.gov
• Cleveland Clinic. Diagnosis and Treatment of Zollinger‑Ellison Syndrome. https://my.clevelandclinic.org
• World Health Organization. WHO Classification of Tumours of the Digestive System, 5th Edition, 2022.
• Javle, M. et al. “Management of Gastrinomas and Zollinger‑Ellison Syndrome.” Gastroenterology 2021;160(5):1485‑1495.

```